PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-65.74%
Negative net income growth while TRAW stands at 154.35%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-40.21%
Both reduce yoy D&A, with TRAW at -7.41%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
147.42%
Deferred tax of 147.42% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-33.50%
Negative yoy SBC while TRAW is 2.28%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
2171.95%
Slight usage while TRAW is negative at -221.95%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
577.15%
AP growth well above TRAW's 123.22%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-447.03%
Both reduce yoy usage, with TRAW at -1586.80%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-33.50%
Negative yoy while TRAW is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-13.29%
Negative yoy CFO while TRAW is 35.97%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
19.79%
CapEx growth of 19.79% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.79%
We expand invests by 19.79% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-207.32%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
104.75%
We slightly raise equity while TRAW is negative at -43.87%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.